BioStock Studio: Scandion Oncology’s CEO comments on ongoing rights issue
Scandion Oncology recently announced that the company is raising 236 MSEK through a fully guaranteed rights issue. The subscription period runs from November 26 through December 10. BioStock caught up with Scandion Oncology’s CEO Bo Rode Hansen via video link to learn more about how the company plans to make the best of the raised capital.
Watch the interview with Scandion Oncology‘s Bo Rode Hansen below:
Also watch the company presentation given by Bo Rode Hansen in connection with the rights issue:
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
